 |
|
L-Deprenyl in Alzheimer's DiseasePreliminary Evidence for Behavioral Change With Monoamine Oxidase B Inhibition
Pierre N. Tariot, MD;
Robert M. Cohen, MD, PhD;
Trey Sunderland, MD;
Paul A. Newhouse, MD;
Donna Yount, RN;
Alan M. Mellow, MD, PhD;
Herbert Weingartner, PhD;
Edward A. Mueller, PhD;
Dennis L. Murphy, MD
Arch Gen Psychiatry. 1987;44(5):427-433.
Abstract
| |
• Since monoamine neurotransmitter disturbances exist in some cases of dementia of the Alzheimer's type (DAT), monoamine-enhancing drugs may ameliorate some symptoms of DAT. L-Deprenyl is a monoamine oxidase (MAO) inhibitor that is generally free of undesired effects. At low doses (10 mg/d) it selectively inhibits MAO-B, an enzyme whose level is elevated in the brains of patients with DAT who are studied post mortem. At higher doses it has more complex effects, including inhibition of MAO-A plus MAO-B. We administered 10 mg/d and 40 mg/d of L-deprenyl to 17 patients with DAT in a double-blind, placebo-controlled, serial treatment. Total Brief Psychiatric Rating Scale scores decreased significantly during 10-mg/d treatment, with decreases in measures of anxiety/depression, tension, and excitement. Approximately one half of the patients' conditions were judged to be improved clinically, with evidence of increased activity and social interaction along with reduced tension and retardation. Similar but smaller changes were observed during 40-mg/d treatment. The behavioral changes were associated with improvement in performance on a complex cognitive task requiring sustained effort. There were minimal physiologic and side effects. The greater effect of low-dose L-deprenyl therapy suggests that it is the inhibition of MAO-B, and not MAO-A, that may be important in the behavioral effects of L-deprenyl administration to patients with DAT.
Author Affiliations
From the Laboratories of Clinical Science (Drs Tariot, Sunderland, Newhouse, Mellow, Mueller, and Murphy and Ms Yount) and Cerebral Metabolism (Dr Cohen), National Institute of Mental Health, Bethesda, Md; the Psychiatry Unit, Monroe Community Hospital, University of Rochester (NY) School of Medicine (Dr Tariot); and the Psychology Department, The George Washington University, Washington, DC (Dr Weingartner).
Footnotes
Accepted for publication Dec 4, 1986.
Reprint requests to Psychiatry Unit, Monroe Community Hospital, University of Rochester School of Medicine, 435 E Henrietta Rd, Rochester, NY 14603 (Dr Tariot).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Current and the near future medications for Alzheimer's disease: What can we expect from them?
Shua-Haim and Ross
AM J ALZHEIMERS DIS OTHER DEMEN 1999;14:294-307.
Physical Aggression Is Associated With Preservation of Substantia Nigra Pars Compacta in Alzheimer Disease
Victoroff et al.
Arch Neurol 1996;53:428-434.
ABSTRACT
Anticonvulsant and Other Non-neuroleptic Treatment of Agitation in Dementia
Tariot et al.
J Geriatr Psychiatry Neurol 1995;8:S28-S39.
ABSTRACT
The Depressions of Alzheimer's Disease: Sorting, Pharmacotherapy, and Clinical Advice
Knesper
J Geriatr Psychiatry Neurol 1995;8:S40-S51.
ABSTRACT
Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review
Patel
J Geriatr Psychiatry Neurol 1995;8:81-95.
ABSTRACT
The treatment of Alzheimer's disease
Allen and Burns
J Psychopharmacol 1995;9:43-56.
High-Dose Selegiline in Treatment-Resistant Older Depressive Patients
Sunderland et al.
Arch Gen Psychiatry 1994;51:607-615.
ABSTRACT
A Pilot Study of Low-Dose L-Deprenyl in Alzheimer's Disease
Schneider et al.
J Geriatr Psychiatry Neurol 1991;4:143-148.
ABSTRACT
Alterations in Brain Monoamine Oxidase Activity in Aging, Alzheimer's Disease, and Pick's Disease
Sparks et al.
Arch Neurol 1991;48:718-721.
ABSTRACT
Drug Treatment of Alzheimer's Disease
Cooper
Arch Intern Med 1991;151:245-249.
ABSTRACT
Pharmacological Treatment of Symptomatic Behaviors in Dementia
Schneider et al.
J Geriatr Psychiatry Neurol 1989;2:57-58.
|
